Lv5
892 积分 2022-03-20 加入
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib
1天前
已完结
Hypoxic niche drives lineage imbalance and early tumorigenesis in EGFR-mutant lung cancer
1天前
已完结
Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 Alterations
12天前
已完结
Reply: Bronchiolocentric interstitial pneumonia is a morphological term used for lung biopsy and chest imaging pattern and is not a substitute for hypersensitivity pneumonitis
15天前
已关闭
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial
25天前
已完结
Molecular Profiling across 80,000 Patients with Lung Cancer
29天前
已完结
ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer
29天前
已完结
GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma
1个月前
已完结
Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
2个月前
已完结
BiTE (CD3×EGFR)-Based Triplet Therapy Unlocks CD40/CD40L Crosstalk to Revert Immunosuppression in third-generation EGFR-TKI-Refractory NSCLC
2个月前
已关闭
皖公网安备34019202002308
